News & Updates
Filter by Specialty:

Botanical compound boosts blood sugar control in prediabetes, early T2D
The novel plant-based polyphenol-rich compound, TOTUM-63, helps keep the lid on fasting plasma glucose (FPG) and other measures of glucose dysregulation in people with prediabetes and early type 2 diabetes (T2D), according to the pivotal phase II/III REVERSE-IT study.
Botanical compound boosts blood sugar control in prediabetes, early T2D
22 Sep 2024
Lack of funds, staffing problem hinder program for kids with obesity
Several barriers on the system and organizational levels disrupt the continuous implementation of SmartMoves, an evidence-based intensive health behaviour and lifestyle treatment (IHBLT) program, for children with obesity, a study has shown.
Lack of funds, staffing problem hinder program for kids with obesity
20 Sep 2024
Low-intensity interventions lower BMI in children with obesity
Low-intensity obesity interventions modestly reduce BMI in children, with one in five kids in the telephonic coaching condition achieving meaningful improvement in BMI z score, reports a recent study.
Low-intensity interventions lower BMI in children with obesity
19 Sep 2024
Automated insulin pump system does not alter energy, nutrient intake in T1D patients
Use of the automated insulin delivery (AID) system delivers better glycaemic control in people with type 1 diabetes (T1D). However, switching to the Minimed 780G insulin pump system does not lead to notable changes in energy and nutrient intake in this population, according to a study.
Automated insulin pump system does not alter energy, nutrient intake in T1D patients
18 Sep 2024
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
17 Sep 2024
GLP-1RA prevents glaucoma development in T2D patients
Use of glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) appears to have protective benefits against the development of glaucoma compared with exposure to other second-line antihyperglycaemic medications, according to a study.
GLP-1RA prevents glaucoma development in T2D patients
17 Sep 2024
Canagliflozin lowers HbA1c in children with T2D
Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.